SCHEMBL3290356

SCHEMBL3290356

CC(=O)OCC(=O)c1cnc(NCC(C)(C)C)cn1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
MAPK8 P45983 1/20 0.33
NUDT1 P36639 1/20 0.33
NCOR1 O75376 1/20 0.33
PCSK9 Q8NBP7 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CHEK1 O14757 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3290355 0.82 NPC1 (0.36) ALDH1A1KMT2AL3MBTL1CHEK1SMN1; SMN2
SCHEMBL1445669 0.64 CNR2 (0.34) ALDH1A1HDAC3HDAC1HDAC2HDAC8
SCHEMBL5361269 0.63 NUDT1 (0.41) MAPK8NUDT1
SCHEMBL6926972 0.63 ALDH1A1 (0.50) ALDH1A1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL5359033 0.62 HPGD (0.40) ALDH1A1KMT2ACHEK1SMN1; SMN2POLB
SCHEMBL882196 0.62 HCAR3 (0.46) ALDH1A1HDAC3HDAC1HDAC2HDAC8
SCHEMBL882378 0.61 HCAR3 (0.57) ALDH1A1HDAC3HDAC1HDAC2HDAC8
SCHEMBL3297481 0.61 CNR2 (0.38) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL17700364 0.60 ALDH1A1 (0.53) ALDH1A1HDAC1HDAC8HDAC6NUDT1
SCHEMBL21427078 0.59 MAPK1 (0.42) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
EP-2145012-A2 MICROBIAL REDUCTION OF AN ACETOXYKETONE F. Hoffmann-Roche AG (CH) 2010-01-20 EP disclosed
WO-2008122511-A2 PROCESS FOR PREPARING 2-AMINO- [5-(1(S), 2-DIHYDROXYETHYL) OR - (KS) -HYDROXY-2-HALOETHYL) ] -PYRAZINE DERIVATIVES BY ENZYMATIC REDUCTION OF THE CORRESPONDING KETONES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-16 WO disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE GCK, HK2, GCKR ALDH1A1 180/4885HDAC3 1351/4885HDAC1 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.